The study, published in Breast Cancer Research and Treatment, retrospectively analyzed 87 women with metastatic triple-negative breast cancer who received Trop-2 antibody-drug conjugates between April 2020 and December 2025. Nearly all patients were treated with sacituzumab govitecan, an antibody-drug conjugate that links a topoisomerase I inhibitor payload to an antibody targeting Trop-2, a cell-surface protein abundantly expressed in triple-negative tumors. Two patients received sacituzumab tirumotecan, a related agent. Patients were divided into three groups: 60 received the antibody-drug conjugate alone, 13 received it together with the PD-1 inhibitor pembrolizumab, and 14 received a triple-agent regimen combining the antibody-drug conjugate, pembrolizumab, and the oral anti-angiogenic drug apatinib. All patients received at least two cycles of therapy in the second-line or later setting.

The results describe a clear stepwise gradient of activity. The objective response rate was 31.7 percent with monotherapy, 38.5 percent with the dual combination, and 57.1 percent with the triple-agent regimen. Disease control rates followed the same pattern, rising from 78.3 percent to 84.6 percent and then to 92.9 percent. More consequential still were the survival figures. Median progression-free survival was 3.8 months with monotherapy, 10.0 months with the dual combination, and 15.4 months with the triple-agent combination, over a median follow-up of 15.2 months. In pooled analysis, any combination therapy was associated with a hazard ratio of 0.387 for progression or death compared with monotherapy, and the benefit persisted after propensity-score-based overlap weighting, with an adjusted hazard ratio of 0.49.

The biological logic underlying the triplet is rooted in the interplay between tumor vasculature and antitumor immunity. Low-dose VEGF pathway inhibition is known to promote vascular normalization within tumors, reversing the hypoxic, immunosuppressive microenvironment that blunts immune checkpoint blockade. Preclinical work has shown that anti-angiogenic therapy enhances CD8-positive T cell activity, and that the OPN-TGF-beta pathway upregulates PD-1 on these T cells, increasing their sensitivity to PD-1 blockade. Clinical evidence has been accumulating in parallel: the ATRACTIB trial suggested that adding bevacizumab to atezolizumab and paclitaxel improved outcomes including in PD-L1-negative disease, and a multicenter phase II trial of camrelizumab, apatinib, and eribulin achieved a 37 percent response rate in heavily pretreated patients regardless of PD-L1 status. The new study extends this concept to an antibody-drug conjugate backbone.

Importantly, the exploratory subgroup analyses suggested that the activity of the triple-agent combination may not be confined to PD-L1-positive tumors. The interaction P-value between treatment effect and PD-L1 status was 0.098, and among the 39 patients with confirmed PD-L1-positive disease, median progression-free survival had not been reached in the triplet group compared with 5.0 months on monotherapy, a statistically significant difference. Prior treatment with a PD-1 inhibitor, documented in roughly half of the cohort, also did not appear to diminish the benefit of the triplet, with an interaction P-value of 0.828. This is clinically meaningful because primary resistance to checkpoint inhibitors occurs in approximately 60 percent of PD-L1-negative triple-negative breast cancers, and immunotherapy rechallenge after progression is often viewed with skepticism.

One of the most intriguing findings emerged from an interaction test involving prior platinum exposure. Among patients who had previously received platinum chemotherapy, the hazard ratio for the triple-agent regimen versus monotherapy was 0.19, a dramatic reduction in the risk of progression or death, whereas among platinum-naive patients the hazard ratio was 1.11, showing essentially no difference. The interaction P-value of 0.039 suggests that platinum-pretreated patients may represent a subgroup particularly likely to benefit from the triplet, possibly because platinum sensitivity reflects underlying DNA damage repair deficiencies that also influence antibody-drug conjugate efficacy. The authors caution that this observation is exploratory and requires prospective validation, but it provides a concrete hypothesis for patient selection in future trials.

Safety data were reassuring. With prophylactic measures applied across the entire cohort, grade 3 or higher treatment-related adverse events occurred in 20.0 percent of monotherapy patients, 15.4 percent of the dual-combination group, and 14.3 percent of the triple-agent group, a difference that was not statistically significant. The most common severe toxicities were leukopenia and neutropenia across all groups. No treatment-related deaths were recorded, and no grade 3 or higher febrile neutropenia, hyperbilirubinemia, rash, or oral ulceration was reported. The starting dose of the antibody-drug conjugate was individualized according to performance status, with patients scoring 2 on the Eastern Cooperative Oncology Group scale receiving reduced starting doses below 80 percent of the standard level. Notably, an antibody-drug conjugate starting dose of at least 80 percent was associated with improved progression-free survival, underscoring the importance of maintaining dose intensity where tolerable.

Beyond the clinical outcomes, the research team developed an exploratory genomic scoring system aimed at identifying which patients are most likely to respond to the triple-agent strategy. The system incorporates mutations in 17 genes connected to Trop-2 antibody-drug conjugate sensitivity, homologous recombination repair, and angiogenesis pathways. Genes promoting therapeutic response, such as ATR, which may sensitize tumors to topoisomerase I inhibition and correlate with higher mutational burden and immunotherapy benefit, received positive weighted scores, while resistance-associated genes received negative scores. Patients whose total score exceeded zero were classified as likely to benefit from the triplet, and Fisher’s exact testing showed the classification was statistically significant. Genes such as VEGFRA and VEGFRB, tied to angiogenesis signaling, may indicate sensitivity to the anti-angiogenic component. The authors emphasize that the model’s principal value at this stage is hypothesis generation rather than clinical deployment.

The study also confirmed several prognostic patterns familiar from earlier research. Patients who initiated antibody-drug conjugate therapy in the second or third line had significantly longer progression-free survival than those treated later, at 5.8 versus 3.0 months. The presence of liver metastases, brain metastases, or visceral disease more broadly each independently predicted shorter progression-free survival after multivariable adjustment, with hazard ratios of 2.38, 2.51, and elevated risk for visceral involvement overall. These findings reinforce that disease biology and metastatic pattern remain dominant determinants of outcome even in the era of antibody-drug conjugates, and they highlight the need for improved risk stratification in biologically aggressive disease.

The investigators are transparent about the limitations inherent in a retrospective, single-center, non-randomized design. Selection bias and residual confounding cannot be excluded, baseline characteristics such as treatment line and PD-L1 status differed descriptively across groups, and the small size of the combination cohorts, 13 and 14 patients respectively, limits statistical power. Sensitivity analyses restricted to second- or third-line patients yielded directionally consistent but non-significant results, likely reflecting reduced sample size. To address these constraints, the team has launched a prospective randomized controlled trial, registered as NCT06851299, designed to rigorously test the efficacy and safety of Trop-2 antibody-drug conjugate-based combination regimens and to validate the genomic risk score. If those results confirm the signals described here, a triplet regimen combining a Trop-2 antibody-drug conjugate, PD-1 blockade, and anti-angiogenic therapy could reshape the treatment algorithm for one of breast cancer’s most lethal forms, extending meaningful survival to patients who currently have few good options.

Subject of Research: Trop-2-directed antibody-drug conjugate monotherapy and combination therapy for pretreated metastatic triple-negative breast cancer

Article Title: Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study

Article References: Liu, J., Ding, L., Wang, J., Chen, T., Long, T., Li, Q., Chai, J., Yao, H., Wang, Y., & Zhao, J. (2026). Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast Cancer Research and Treatment, 219(2), Article 10. https://doi.org/10.1007/s10549-026-08070-9

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08070-9

Keywords: Trop-2 antibody-drug conjugates, metastatic triple-negative breast cancer, sacituzumab govitecan, PD-1 inhibitors, anti-angiogenic therapy, triple-agent combination therapy, pembrolizumab, apatinib, progression-free survival, biomarker-guided therapy, real-world study, immune checkpoint inhibitors

Triple-negative breast cancer represents a formidable challenge in oncological care, accounting for approximately 15% of breast cancer diagnoses worldwide. Characterized by the absence of estrogen receptors, progesterone receptors, and HER2 amplification, TNBC is notoriously difficult to treat, with a five-year survival rate for metastatic cases lingering near a dire 15%. The therapeutic void is exacerbated for nearly 60% of metastatic TNBC patients whose tumors do not express PD-L1, rendering immune checkpoint inhibitor therapies ineffective and narrowing treatment options significantly.

Conventional treatment modalities for TNBC have predominantly relied on chemotherapy, which, while somewhat effective, often fall short in yielding durable responses, especially among those with PD-L1-negative tumors. The urgent need for innovative, targeted therapies lagged behind scientific progress—until now. Sacituzumab govitecan, an antibody-drug conjugate (ADC), emerges as a beacon of targeted precision medicine. Its mechanism hinges on binding to Trop2, a protein abundantly expressed on the surface of TNBC cells, thereby facilitating the direct delivery of a potent cytotoxic agent to the malignancies, circumventing systemic toxicity often associated with traditional chemotherapy.

The ASCENT-03 trial, encompassing a vast cohort of 558 patients across 229 clinical sites in 30 countries, robustly evaluated the efficacy of sacituzumab govitecan as a first-line treatment against the prevailing standard chemotherapy regimens in individuals with locally advanced or unresectable TNBC lacking eligibility for immune checkpoint inhibitors. Nearly all patients—about 99%—within both study arms presented PD-L1-negative tumors, ensuring a well-defined population reflective of an unmet clinical need.

After a median follow-up period surpassing 13 months, the outcomes conveyed a compelling narrative. Patients receiving sacituzumab govitecan exhibited a median progression-free survival (PFS) of 9.7 months, notably outperforming the 6.9 months observed in the chemotherapy arm. Furthermore, patients who responded to sacituzumab govitecan treatment maintained their response for a median duration of 12.2 months, contrasting starkly with the 7.2-month median response duration among chemotherapy responders. These data underscore not only enhanced disease control but also prolonged therapeutic benefit, heralding a potentially paradigm-shifting approach in frontline TNBC management.

Although overall survival data remain in preliminary stages and require further maturation, safety analyses affirm that sacituzumab govitecan’s adverse effect profile is well-characterized, coherent with previous clinical experiences, and manageable within established guidelines employing supportive care strategies. This tolerability is pivotal, given the aggressive nature of TNBC and the critical imperative to maintain quality of life during treatment.

Experts in oncology, including Dr. Sara Tolaney from Dana-Farber Cancer Institute, highlighted the significance of these findings, emphasizing the strategic advantage of integrating more effective drugs like sacituzumab govitecan earlier in the treatment sequence. This proactive approach aims to maximize the depth and durability of tumor responses, potentially translating into improved survival outcomes and quality of life for patients historically confronted with limited options and dismal prognoses.

Sacituzumab govitecan’s journey to this milestone is rooted in foundational clinical research conducted at institutions such as Dana-Farber. Initial studies delineated the ADC’s safety and effectiveness profile, culminating in its initial U.S. FDA approval as a second-line therapy for advanced TNBC. However, clinical observations revealed that nearly half of TNBC patients do not advance to second-line treatment, underscoring the clinical imperative to shift effective interventions like sacituzumab govitecan to frontline therapy.

In addition to its application in triple-negative breast cancer, sacituzumab govitecan has demonstrated efficacy in hormone receptor-positive, HER2-negative metastatic breast cancer, as validated by the pivotal TROPiCS-02 clinical trial. This broader applicability underscores the versatility of ADC technology targeting Trop2 and presents a platform for further combinatorial strategies in breast cancer therapeutics.

Recent advancements further include data from the ASCENT-04/KEYNOTE-D19 trial evaluating the synergy between sacituzumab govitecan and pembrolizumab—an immune checkpoint inhibitor—illustrating enhanced durable responses and progression-free survival for patients with PD-L1-positive metastatic TNBC. These findings highlight a nuanced landscape where immune status biomarkers guide therapeutic combinations, tailoring approaches to tumor biology.

The ASCENT-03 trial not only elucidates a new standard of care for a challenging patient subset but also exemplifies the convergence of precision oncology, translational research, and global collaborative clinical investigation. Supported by Gilead Sciences, Inc., this endeavor advances the mission to diminish the burden of metastatic TNBC through scientifically driven, patient-centric innovation.

Dana-Farber Cancer Institute remains at the forefront of this pioneering work, distinguished as a global leader in cutting-edge oncology research and patient care. As a federally designated Comprehensive Cancer Center and an affiliate of Harvard Medical School, Dana-Farber champions a model where scientific discovery seamlessly integrates with clinical application, empowering patients through access to more than 1,200 clinical trials and novel therapies.

In summary, sacituzumab govitecan’s demonstrated superiority over standard chemotherapy in PD-L1-negative, treatment-naïve TNBC patients heralds a new era of targeted therapy in a historically refractory and aggressive cancer subtype. This breakthrough encapsulates the promise of antibody-drug conjugates to revolutionize cancer treatment paradigms by delivering cytotoxic agents directly to malignant cells while minimizing systemic exposure. Ongoing follow-up and further clinical investigation will solidify sacituzumab govitecan’s role and optimal use in the clinical armamentarium against triple-negative breast cancer.

Subject of Research: Therapeutic efficacy of sacituzumab govitecan in untreated, advanced triple-negative breast cancer patients ineligible for immune checkpoint inhibitor therapy.

Article Title: Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

News Publication Date: October 19, 2025

Web References:

• European Society for Medical Oncology (ESMO) Congress 2025
• New England Journal of Medicine Article
• Dana-Farber Cancer Institute

References: ASCENT-03 clinical trial data; FDA approvals; TROPiCS-02 and ASCENT-04/KEYNOTE-D19 trial publications.

Keywords: Breast cancer, Triple-negative breast cancer, Sacituzumab govitecan, Antibody-drug conjugate, Progression-free survival, PD-L1 negative tumors, Targeted therapy, ADC, Chemotherapy, Immune checkpoint inhibitors.